Black Diamond Therapeutics
BDTX
96 hedge funds and large institutions have $212M invested in Black Diamond Therapeutics in 2024 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 38 increasing their positions, 21 reducing their positions, and 16 closing their positions.
81% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 21
38% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 16
7% more funds holding
Funds holding: 90 → 96 (+6)
3.08% more ownership
Funds ownership: 83.13% → 86.21% (+3.1%)
3% less capital invested
Capital invested by funds: $218M → $212M (-$6.02M)
27% less call options, than puts
Call options by funds: $7.04M | Put options by funds: $9.61M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
+$15.9M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$3.8M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$3.79M |
| 4 |
OCA
Octagon Capital Advisors
New York
|
+$3.23M |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
+$1.55M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$4.88M |
| 2 |
Millennium Management
New York
|
-$4.23M |
| 3 |
ABG
Ally Bridge Group
New York
|
-$3.89M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$3.78M |
| 5 |
SC
Stempoint Capital
New York
|
-$3.14M |
BDTX Hedge Fund Activity: Q3 2024 in Review
96 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Black Diamond Therapeutics (BDTX) for Q3 2024, worth a combined $212M — down 2.8% from $218M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new BDTX positions and 16 closed out — a net gain of 6 holders — while 38 added to existing stakes and 21 trimmed.
The largest buyer was Vestal Point Capital, adding an estimated $15.9M. The largest seller was Artal Group, exiting entirely with an estimated $4.88M sold.
- 96 institutional investors held Black Diamond Therapeutics (BDTX) as of Q3 2024, up from 90 in Q2 2024.
- Funds reported $212M of Black Diamond Therapeutics stock for Q3 2024, down 2.8% quarter-over-quarter.
- 22 funds opened new Black Diamond Therapeutics positions in Q3 2024 and 16 closed out, a net change of +6 holders.
- The largest Black Diamond Therapeutics buyer in Q3 2024 was Vestal Point Capital, an estimated $15.9M added.
- The largest Black Diamond Therapeutics seller in Q3 2024 was Artal Group, an estimated $4.88M sold.
Based on aggregated 13F filings for Q3 2024.